CSF2 and melanoma: In a further trial, Finocchiaro and Gilkin combined autologous/allogeneic formolized tumor cells as a vaccine injected concomitantly with lethally irradiated xenogeneic cells producing human GM-CSF to treat canine malignant melanoma patients [26].